AnGes, Inc. and Er-Kim announced an exclusive licensing and distribution agreement for Er-Kim to commercialize AnGes’ gene therapy product Collategene® for Critical Limb Ischemia patients in Turkey. Under the terms of the agreement, Er-Kim will have the exclusive rights to commercialize Collategene® in Turkey after obtaining the necessary regulatory approvals. After the approval of the product, Er-Kim will be responsible for sales, marketing and local medical affairs activities as it relates to Collategene®. Moreover, AnGes and Er-Kim will make Collategene® immediately available through Named Patient Program prior to approval.